diabetestalk.net

Mitochondrial Diabetes Treatment

Mitochondrial Dynamics In Type 2 Diabetes: Pathophysiological Implications - Sciencedirect

Mitochondrial Dynamics In Type 2 Diabetes: Pathophysiological Implications - Sciencedirect

Mitochondria play a key role in maintaining cellular metabolic homeostasis. These organelles have a high plasticity and are involved in dynamic processes such as mitochondrial fusion and fission, mitophagy and mitochondrial biogenesis. Type 2 diabetes is characterised by mitochondrial dysfunction, high production of reactive oxygen species (ROS) and low levels of ATP. Mitochondrial fusion is modulated by different proteins, including mitofusin-1 (MFN1), mitofusin-2 (MFN2) and optic atrophy (OPA-1), while fission is controlled by mitochondrial fission 1 (FIS1), dynamin-related protein 1 (DRP1) and mitochondrial fission factor (MFF). PARKIN and (PTEN)-induced putative kinase 1 (PINK1) participate in the process of mitophagy, for which mitochondrial fission is necessary. In this review, we discuss the molecular pathways of mitochondrial dynamics, their impairment under type 2 diabetes, and pharmaceutical approaches for targeting mitochondrial dynamics, such as mitochondrial division inhibitor-1 (mdivi-1), dynasore, P110 and 15-oxospiramilactone. Furthermore, we discuss the pathophysiological implications of impaired mitochondrial dynamics, especially in type 2 diabetes. Continue reading >>

Advice On Mitochondria Diabetes And Treatment

Advice On Mitochondria Diabetes And Treatment

Diabetes Forum The Global Diabetes Community This site uses cookies. By continuing to use this site, you are agreeing to our use of cookies. Learn More. Get the Diabetes Forum App for your phone - available on iOS and Android . Find support, ask questions and share your experiences. Join the community advice on mitochondria diabetes and treatment Does anyone know anything about the rare mitochondria diabetes as im in the middle of full diagnosis and find internet explanations too technical to understand? About 1% of people with diabetes have Maternally-Inherited Diabetes and Deafness (MIDD) rather than Type 1 or Type 2. MIDD is caused by a mutation in the DNA of the mitochondria - the parts of the cell involved in producing energy. We all inherit our mitochondria from our mothers, not our fathers so MIDD, like other mitochondrial diseases is inherited through the female line. The diabetes can resemble Type 1 or Type 2 and the deafness varies a lot between individuals - it tends to affect high-pitched noises most and men are usually worse affected than women. If you go to this page and click the "information sheet" button on the right, you can download a document which explains it quite simply. Continue reading >>

Diabetes Mellitus Associated With 3243 Mitochondrial Trnaleu(uur) Mutation: Clinical Features And Coenzyme Q10 Treatment

Diabetes Mellitus Associated With 3243 Mitochondrial Trnaleu(uur) Mutation: Clinical Features And Coenzyme Q10 Treatment

Diabetes mellitus associated with 3243 mitochondrial tRNALeu(UUR) mutation: Clinical features and coenzyme Q10 treatment Get rights and content Diabetes mellitus associated with mitochondrial tRNA mutation at position 3243 (DM-Mt3243) is a new disease. Patients have a distinctly different picture from MELAS (mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes). During observations at the Saiseikai Central Hospital, the following findings were noted in DM-Mt3243 patients: DM-Mt3243 patients are diagnosed earlier with diabetes, compared to NIDDM (non-insulin dependent diabetes mellitus) controls without family history. DM-Mt3243 patients often need insulin more often than NIDDM controls without family history. Post-treatment neuropathy and insulin edema are often found in DM-Mt3243, and the two phenomena possibly have a similar pathophysiology related to mitochondrial dysfunction. Ambiguous psychiatric disorders of functional psychosis are observed frequently in DM-Mt3243. Mild headache is common in DM-Mt3243 cases. Ambiguous neuromuscular abnormaltiies such as sleep disturbance, paresthesia of the legs, edema of the legs, and palpitation may be symptoms associated with mitochondrial dysfunction in DM-Mt3243. Coenzyme Q may be effective in the relief of these neuromuscular symptoms. Continue reading >>

Mitochondrial Dysfunction And Insulin Resistance: An Update

Mitochondrial Dysfunction And Insulin Resistance: An Update

Abstract Mitochondrial dysfunction has been implicated in the development of insulin resistance (IR); however, a large variety of association and intervention studies as well as genetic manipulations in rodents have reported contrasting results. Indeed, even 39 years after the first publication describing a relationship between IR and diminished mitochondrial function, it is still unclear whether a direct relationship exists, and more importantly if changes in mitochondrial capacity are a cause or consequence of IR. This review will take a journey through the past and summarise the debate about the occurrence of mitochondrial dysfunction and its possible role in causing decreased insulin action in obesity and type 2 diabetes. Evidence is presented from studies in various human populations, as well as rodents with genetic manipulations of pathways known to affect mitochondrial function and insulin action. Finally, we have discussed whether mitochondria are a potential target for the treatment of IR. Mitochondrial function Mitochondria, originating from bacterial precursor cells that were able to generate energy, provide a platform for the generation of ATP, the energy currency of the cell. As ATP is essential for many cellular processes, mitochondrial function (and mitochondrial dysfunction) plays an important role in metabolic health and cellular fate. Mitochondrial function can be defined in a number of different ways, but for the purpose of this review we have largely focussed on the role of mitochondria in metabolic processes including oxidative phosphorylation and substrate oxidation (summarised in Fig. 1). The regulation of mitochondrial function is complex and still not fully understood. It involves rapid adaptations to changing metabolic conditions, such as fusio Continue reading >>

The Effects Of Coenzyme Q10 Treatment On Maternally Inherited Diabetes Mellitus And Deafness, And Mitochondrial Dna 3243 (a To G) Mutation.

The Effects Of Coenzyme Q10 Treatment On Maternally Inherited Diabetes Mellitus And Deafness, And Mitochondrial Dna 3243 (a To G) Mutation.

The effects of coenzyme Q10 treatment on maternally inherited diabetes mellitus and deafness, and mitochondrial DNA 3243 (A to G) mutation. Third Department of Internal Medicine, Tohoku University School of Medicine, Sendai, Japan. The characteristic clinical features of diabetes mellitus with mitochondrial DNA (mtDNA) 3243(A-G) mutation are progressive insulin secretory defect, neurosensory deafness and maternal inheritance, referred to as maternally inherited diabetes mellitus and deafness (MIDD). A treatment for MIDD to improve insulin secretory defects and reduce deafness has not been established. The effects of coenzyme Q10 (CoQ10) treatment on insulin secretory response, hearing capacity and clinical symptoms of MIDD were investigated. 28 MIDD patients (CoQ10-DM), 7 mutant subjects with impaired glucose tolerance (IGT), and 15 mutant subjects with normal glucose tolerance (NGT) were treated daily with oral administration of 150 mg of CoQ10 for 3 years. Insulin secretory response, blood lactate after exercise, hearing capacity and other laboratory examinations were investigated every year. In the same way we evaluated 16 MIDD patients (control-DM), 5 mutant IGT and 5 mutant NGT subjects in yearly examinations. The insulin secretory response assessed by glucagon-induced C-peptide secretion and 24 h urinary C-peptide excretion after 3 years in the CoQ10-DM group was significantly higher than that in the control-DM group. CoQ10 therapy prevented progressive hearing loss and improved blood lactate after exercise in the MIDD patients. CoQ10 treatment did not affect the diabetic complications or other clinical symptoms of MIDD patients. CoQ10 treatment did not affect the insulin secretory capacity of the mutant IGT and NGT subjects. There were no side effects during the Continue reading >>

Swiss Medical Weekly - Precision Medicine For Monogenic Diabetes: From A Survey To The Development Of A Next-generation Diagnostic Panel

Swiss Medical Weekly - Precision Medicine For Monogenic Diabetes: From A Survey To The Development Of A Next-generation Diagnostic Panel

Precision medicine for monogenic diabetes: from a survey to the development of a next-generation diagnostic panel Sakina Kherra,Jean-Louis Blouin,Federico Santoni,Valerie Schwitzgebel Monogenic diabetes (MD) accounts for 12% of all diabetes cases. Because of its wide phenotypic spectrum, MD is often misdiagnosed as type 1 or type 2 diabetes. While clinical and biochemical parameters can suggest MD, a definitive diagnosis requires genetic analysis. We conducted a survey among clinicians specialising in diabetes to document the cases with MD. Of 74 clinically suspected MD patients, 46% had undergone genetic analysis, which was mostly conducted using Sangers classical sequencing method. The most common recorded mutations were located in the GCK gene, followed by the mitochondrial genome (m.3243A>G mutation) and the HNF1B and HNF1A genes. The remaining 54% of patients only had a clinical diagnosis, mostly because genetic analysis was not easily accessible. Here, we designed a new diagnostic panel of 42 genes that was developed based on the survey. The panel was validated with an independent sample of nine known MD patients. Our survey confirms the need for a comprehensive analytical instrument for the diagnosis of MD, which will be met by the proposed panel. The diagnosis of MD is crucial because it dictates treatment and may improve metabolic control and reduce long-term complications as proposed by precision medicine. Keywords:next-generation sequencing, pancreas, personalised medicine, diabetes, neonatal diabetes, precision medicine, genetic diabetes, autoimmune, type 1 diabetes, type 2 diabetes, monogenic diabetes Monogenic diabetes (MD), in contrast to polygenic type 1 and type 2 diabetes, is due to a single gene defect and has traditionally been referred to as maturi Continue reading >>

Payperview: Diabetes Mellitus In Mitochondrial Disease - Karger Publishers

Payperview: Diabetes Mellitus In Mitochondrial Disease - Karger Publishers

Diabetes Mellitus in Mitochondrial Disease Prof. Robert W. Taylor or Dr. Andrew M. Schaefer Wellcome Trust Centre for Mitochondrial Research, Institute of Neuroscience The Medical School, Newcastle University, Framlington Place E-Mail [email protected], [email protected] I have read the Karger Terms and Conditions and agree. Mitochondrial diseases arise as a consequence of respiratory chain dysfunction caused by mutations in the mitochondrial genome (mtDNA) or nuclear-encoded mitochondrial genes. Multisystem involvement is a hallmark of many subtypes of mitochondrial disease in which energy-dependent organs including the brain, skeletal muscles, and heart are commonly affected. The most common mitochondrial genotype that causes diabetes mellitus is a single nucleotide substitution (m.3243A>G) in the mitochondrial tRNALeu(UUR) gene which is linked to a distinctive clinical phenotype - maternally inherited diabetes and deafness. Diabetes mellitus often arises insidiously as part of the clinical presentation associated with mitochondrial disease; however, there are unique clinical features and associated complications compared to other diabetes subtypes. Overall, the treatment of patients with mitochondrial diabetes is similar to those with other causes of diabetes but with additional emphasis on the screening and subsequent management of additional multiorgan involvement. Ballinger SW, Shoffner JM, Hedaya EV, Trounce I, Polak MA, Koontz DA, et al: Maternally transmitted diabetes and deafness associated with a 10.4 kb mitochondrial DNA deletion. Nat Genet 1992;1:11-15. van den Ouweland JM, Lemkes HH, Ruitenbeek W, Sandkuijl LA, de Vijlder MF, Struyvenberg PA, et al: Mutation in mitochondrial tRNA(Leu)(UUR) gene in a large pedigree with maternally tra Continue reading >>

Mitochondrial Diabetes

Mitochondrial Diabetes

Around 1% of all cases of diabetes are due to mutations in the mitochondrial DNA (mtDNA). The commonest mutation is the m.3243A>G, associated with the maternally inherited diabetes and deafness (MIDD) syndrome. Patients with MIDD are often misclassified as type 2 or type 1 diabetes by physicians unaware of the syndrome. The presence of diabetes, deafness and a family history of the above in maternal relatives should raise suspicion of MIDD and genetic testing should be pursued in view of the implications for personalised management and genetic counselling for patients and relatives. Diabetes is treated initially with oral hypoglycaemics, but early use of insulin is commonly needed due to insulin deficiency. Maternally inherited diabetes and deafness (MIID/; MIM no. 520000) is a rare form of diabetes, accounting for approximately 1% of all diabetes cases [1] , first described in 1992 by van den Ouweland et al in a Dutch family and by Reardon et al in a UK family [2] [3] . This quite heterogeneous syndrome results from an A to G substitution at the conserved position 3243 (m.3243A>G) of the mitochondrial DNA. The age and the mode of presentation of diabetes result in this entity being often misdiagnosed as either T1D or T2D. The presence of diabetes and sensorineural deafness in a patient with family history of similar problems in maternal relatives should raise suspicion of MIDD. However, a number of other features may co-exist (see below). The clinical characteristics of diabetes can be similar to either T1D or T2D depending on the degree of insulinopenia. The presentation is usually insidious as in T2D, however around 20% of cases present acutely, even with ketoacidosis in a small proportion. Interestingly, in the vast majority of MIDD patients there is lack of autoim Continue reading >>

Mitochondrial Disease

Mitochondrial Disease

This article needs additional citations for verification . Please help improve this article by adding citations to reliable sources . Unsourced material may be challenged and removed. ( Learn how and when to remove this template message ) Micrograph showing ragged red fibers, a finding seen in various types of mitochondrial diseases. Muscle biopsy . Gomori trichrome stain . Mitochondrial diseases are a group of disorders caused by dysfunctional mitochondria , the organelles that generate energy for the cell. Mitochondria are found in every cell of the human body except red blood cells , and convert the energy of food molecules into the ATP that powers most cell functions. Mitochondrial diseases are sometimes (about 15% of the time) [1] caused by mutations in the mitochondrial DNA that affect mitochondrial function. Other mitochondrial diseases are caused by mutations in genes of the nuclear DNA , whose gene products are imported into the mitochondria ( mitochondrial proteins ) as well as acquired mitochondrial conditions. Mitochondrial diseases take on unique characteristics both because of the way the diseases are often inherited and because mitochondria are so critical to cell function. The subclass of these diseases that have neuromuscular disease symptoms are often called a mitochondrial myopathy . Symptoms include poor growth, loss of muscle coordination, muscle weakness, visual problems, hearing problems, learning disabilities, heart disease, liver disease, kidney disease, gastrointestinal disorders, respiratory disorders, neurological problems, autonomic dysfunction and dementia. Acquired conditions in which mitochondrial dysfunction has been involved are: diabetes, Huntington's disease, cancer, Alzheimer's disease, Parkinson's disease, bipolar disorder , [2] [3 Continue reading >>

Orphanet: Mitochondrial Diabetes

Orphanet: Mitochondrial Diabetes

The prevalence is unknown, but MIDD accounts for 0.2-3% of all cases of diabetes. The first manifestations may occur at any age, but the disease is usually diagnosed in early adulthood. In most cases, the onset of deafness precedes that of diabetes. The severity of the hearing loss is variable but it is sensorineural, bilateral and progressive, and is more profound at higher frequencies. In most cases, patients present pseudo-type 2 diabetes, with a normal or low body mass index. Pseudo-type 1 diabetes, sometimes with ketoacidosis, is observed in 20% of cases. Diabetic retinopathy is less common in MIDD patients than in those with classic forms of diabetes. In more than 80% of cases, patients develop specific macular pattern dystrophy lesions that are only seen in MIDD patients and are asymptomatic in most cases. Organs with high metabolic activity (muscles, myocardium, kidney, and brain) are frequently affected potentially leading to muscle pain, gastrointestinal tract symptoms, nephropathy, cardiomyopathy, and neuropsychiatric symptoms. In most cases, MIDD is caused by a point mutation in the mitochondrial gene MT-TL1, encoding the mitochondrial tRNA for leucine, and in rare cases in MT-TE and MT-TK genes, encoding the mitochondrial tRNAs for glutamic acid, and lysine, respectively. Diagnosis is based on the clinical picture and patient history. Measurements of fasting plasma glucose levels allow diagnosis of the diabetes. Ophthalmologic examination reveals the disease-specific macular pattern dystrophy. The diagnoses of standard type 2 and type 1 diabetes are excluded by the presence of the deafness, low body weight and the specific macular pattern dystrophy, and by evidence of maternal transmission. Management is symptomatic. Oral antidiabetic agentsand/or insulin Continue reading >>

Pyruvate Improved Insulin Secretion Status In A Mitochondrial Diabetes Mellitus Patient

Pyruvate Improved Insulin Secretion Status In A Mitochondrial Diabetes Mellitus Patient

Mitochondrial diabetes is a rare form of diabetes mellitus accounting for up to 1% of all diabetes. Pyruvate therapy has been reported to be a potential therapeutic choice for patients with mitochondrial diseases. Water-based sodium pyruvate solutions (0.5 g/kg, thrice daily) were administrated orally to a 32-year-old Japanese male with mitochondrial diabetes and myopathy caused by m.14709T>C mutation. At the age of 20 years, he was diagnosed with diabetes mellitus and started insulin therapy. He tested negative for islet cell and glutamic decarboxylase antibodies. To evaluate favorable therapeutic improvements, we measured the lactate and pyruvate levels in plasma and cerebrospinal fluid; urinary C-peptide, glycated hemoglobin, and glycoalbumin levels; and total daily insulin dose (TDD). The patient experienced no side effects such as diarrhea because of pyruvate therapy. His urinary C-peptide level improved from 4.3 to 17.2 g/d after 1 day and to 30.2 g/d after 6 months of pyruvate therapy. TDD decreased from 33 to 20 U/d after 6 months of pyruvate therapy, but the lactate levels of plasma and cerebrospinal fluid and the lactate/pyruvate ratio did not change. Sodium pyruvate improved insulin secretion and resulted in decreased TDD in a patient with mitochondrial diabetes. Pyruvate therapy may be a potential therapeutic choice for patients with mitochondrial diabetes. Clinical trials involving a larger number of patients and long-term evaluation of the therapy are necessary to clarify the efficacy of pyruvate therapy. In a mitochondrial disorder, there is a metabolic block in oxidative phosphorylation; this disorder shows a large spectrum of symptoms, such as muscle weakness, encephalopathy, impaired hearing, and diabetes mellitus (DM). Dysfunctional mitochondria in t Continue reading >>

Omim Entry - # 520000 - Diabetes And Deafness, Maternally Inherited; Midd

Omim Entry - # 520000 - Diabetes And Deafness, Maternally Inherited; Midd

A number sign (#) is used with this entry because of evidence that the disorder can be caused by mutation in several mitochondrial genes, including MTTL1 ( 590050 ), MTTE ( 590025 ), and MTTK ( 590060 ). The most common mutation is a 3243A-G transition in the MTTL1 gene ( 590050.0001 ). Maternally inherited diabetes-deafness syndrome (MIDD) is a mitochondrial disorder characterized by onset of sensorineural hearing loss and diabetes in adulthood. Some patients may have additional features observed in mitochondrial disorders, including pigmentary retinopathy, ptosis, cardiomyopathy, myopathy, renal problems, and neuropsychiatric symptoms ( Ballinger et al., 1992 ; Reardon et al., 1992 ; Guillausseau et al., 2001 ). The association of diabetes and deafness is observed with Wolfram syndrome (see 222300 ), Rogers syndrome ( 249270 ), and Herrmann syndrome ( 172500 ), but all 3 of these disorders have other clinical manifestations. Kressmann (1976) reported a large family in which diabetes and deafness were transmitted over 4 generations, with a total of 13 affected individuals. The clinical history was the same for all affected patients: the first manifestation was deafness, beginning at 20 to 30 years of age, with a rapid and severe increase in bilateral sensory hearing loss. Diabetes mellitus developed later in the third decade, and insulin was required either immediately or at a later date. At that time, persons from the fourth generation who were less than 20 years of age presented no deafness or diabetes. No pedigree member had ptosis, ophthalmoplegia, or muscle weakness. Reexamination of members of the family by Negrier et al. (1998) demonstrated no ragged-red fibers on skeletal muscle biopsy specimens and very limited lipid storage on electron microscopy. Ballinger Continue reading >>

Maternally-inherited Diabetes With Deafness (midd) And Hyporeninemic Hypoaldosteronism

Maternally-inherited Diabetes With Deafness (midd) And Hyporeninemic Hypoaldosteronism

CASE REPORT Diabetes mitocondrial (MIDD) e hipoaldosteronismo hiporreninêmico Patricia B. Mory; Marcia C. dos Santos; Claudio E. Kater; Regina S. Moisés Disciplina de Endocrinologia, Escola Paulista de Medicina, Universidade Federal de São Paulo (Unifesp-EPM), São Paulo, SP, Brazil SUMMARY Maternally-inherited diabetes with deafness (MIDD) is a rare form of monogenic diabetes that results, in most cases, from an A-to-G transition at position 3243 of mitochondrial DNA (m.3243A>G) in the mitochondrial-encoded tRNA leucine (UUA/G) gene. As the name suggests, this condition is characterized by maternally-inherited diabetes and bilateral neurosensory hearing impairment. A characteristic of mitochondrial cytopathies is the progressive multisystemic involvement with the development of more symptoms during the course of the disease. We report here the case of a patient with MIDD who developed hyporeninemic hypoaldosteronism. Arq Bras Endocrinol Metab. 2012;56(8):574-7 SUMÁRIO O diabetes mitocondrial (MIDD) é uma forma rara de diabetes monogênico resultante, na maioria dos casos, da mutação mitocondrial A3243G. Essa condição é caracterizada por diabetes de transmissão materna e disacusia neurossensorial. Uma característica das mitocondriopatias é o envolvimento progressivo de outros órgãos ou sistemas, levando ao aparecimento de diversos sintomas durante o curso da doença. Este relato descreve o caso de um paciente com MIDD que, durante o período de acompanhamento, apresentou hipoaldosteronismo hiporreninêmico. Arq Bras Endocrinol Metab. 2012;56(8):574-7 INTRODUCTION Maternally inherited diabetes and deafness (MIDD) (OMIM # 520000) is a rare form of diabetes that results, in most cases, from an A-to-G transition at position 3243 of mitochondrial DNA (m.3243A> Continue reading >>

Mitochondrial Diabetes In Children: Seek And You Will Find It

Mitochondrial Diabetes In Children: Seek And You Will Find It

Abstract Maternally Inherited Diabetes and Deafness (MIDD) is a rare form of diabetes due to defects in mitochondrial DNA (mtDNA). 3243 A>G is the mutation most frequently associated with this condition, but other mtDNA variants have been linked with a diabetic phenotype suggestive of MIDD. From 1989 to 2009, we clinically diagnosed mitochondrial diabetes in 11 diabetic children. Diagnosis was based on the presence of one or more of the following criteria: 1) maculopathy; 2) hearing impairment; 3) maternal heritability of diabetes/impaired fasting glucose and/or hearing impairment and/or maculopathy in three consecutive generations (or in two generations if 2 or 3 members of a family were affected). We sequenced the mtDNA in the 11 probands, in their mothers and in 80 controls. We identified 33 diabetes-suspected mutations, 1/33 was 3243A>G. Most patients (91%) and their mothers had mutations in complex I and/or IV of the respiratory chain. We measured the activity of these two enzymes and found that they were less active in mutated patients and their mothers than in the healthy control pool. The prevalence of hearing loss (36% vs 75–98%) and macular dystrophy (54% vs 86%) was lower in our mitochondrial diabetic adolescents than reported in adults. Moreover, we found a hitherto unknown association between mitochondrial diabetes and celiac disease. In conclusion, mitochondrial diabetes should be considered a complex syndrome with several phenotypic variants. Moreover, deafness is not an essential component of the disease in children. The whole mtDNA should be screened because the 3243A>G variant is not as frequent in children as in adults. In fact, 91% of our patients were mutated in the complex I and/or IV genes. The enzymatic assay may be a useful tool with which to Continue reading >>

Diabetes Mellitus And Deafness

Diabetes Mellitus And Deafness

Diabetes mellitus and deafness (DAD) or maternally inherited diabetes and deafness (MIDD) is a subtype of diabetes which is caused from a point mutation at position 3243 in human mitochondrial DNA, which consists of a circular genome. This affects the gene encoding tRNALeu.[1][2] Because mitochondrial DNA is contributed to the embryo by the oocyte and not by spermatozoa, this disease is inherited from maternal family members only.[1] As indicated by the name, MIDD is characterized by diabetes and sensorineural hearing loss.[1] Signs and symptoms[edit] As suggested by the name, MIDD patients are subject to sensorineural hearing loss.[1] This begins with a reduction in the perception of frequencies above approximately 5 kHz which progressively declines, over the years, to severe hearing loss at all frequencies.[1] The diabetes that accompanies the hearing loss can be similar to Type 1 diabetes or Type 2 diabetes; however, Type 1-like diabetes is the more common form of the two. MIDD has also been associated with a number of other issues including kidney dysfunction, gastrointestinal problems, and cardiomyopathy.[3] Genetics[edit] Penetrance and age of onset[edit] MIDD represents 1% of patients with diabetes. Over 85% of people that carry the mutation in mitochondrial DNA at position 3243 present symptoms of diabetes. The average age at which MIDD patients are typically diagnosed is 37 years old but has been seen to range anywhere between 11 years to 68 years old. Of these diabetic patients carrying the mitochondrial DNA mutation at position 3243, 75% experience sensorineural hearing loss.[1] In these cases, hearing loss normally appears before the onset of diabetes and is marked by a decrease in perception of high tone frequencies.[3] The associated hearing loss with diab Continue reading >>

More in diabetes